$2.19
arrow_drop_down8.75%Key Stats | |
---|---|
Open | $2.38 |
Prev. Close | $2.40 |
EPS | -1.38 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $106.19M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 2.14 | 2.38 |
52 Week Range | 1.57 | 8.19 |
Ratios | |
---|---|
EPS | -1.38 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Where Werewolf Therapeutics Stands With Analysts
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
Critical Insights From Werewolf Therapeutics Analyst Ratings: What You Need To Know
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
The Analyst Verdict: Werewolf Therapeutics In The Eyes Of 4 Experts